

Curriculum Vitae



Informazioni personali

Stefania Chiappini
Italiana

17.08.1984

F

Residenza
Tel.
Email:

stefaniachiappini9@gmail.com

SCOPUS (30.08.2023)

1,136 Citations by 901 documents

57 Documents

h-index 20

Esperienza lavorativa

Da Ottobre 2023

**Ricercatore a tempo determinato e definito– SC: 06/D5 Psichiatria, SSD: MED/25
UniCamillus- - Saint Camillus International University of Health and Medical Sciences**

Luglio 2022/Giugno 2023

Postdoc fellowship

School of Life and Medical Sciences - Allied Health Professions, Dentistry, Nursing and Pharmacy
Department of Clinical, Pharmaceutical and Biological Sciences
University of Hertfordshire, Hatfield, Herts (UK)

Giugno 2020/ Dicembre 2021

Research grant

Università G. D'Annunzio -Chieti (CH), IT

Coordinatore dello studio multicentrico VESPA (Vortioxetine in the Elderly vs SSRIs: a pragmatic assessment)

Maggio 2019/ad oggi

Dirigente Medico Psichiatra

Struttura Residenziale Psichiatrica accreditata con il Servizio Sanitario Nazionale Villa Maria Pia- Roma (IT)

Medico di reparto presso: STPIT (Struttura di Trattamento Psichiatrico Intensivo Territoriale) e SRSR H24 (Struttura Residenziale Socio-Riabilitativa ad elevata intensità assistenziale socio-sanitaria)

Studi effettuati in collaborazione con l'Università G. D'Annunzio di Chieti:

- Partecipazione in qualità di sub-investigatore al progetto di ricerca: Abilify Maintena® in SCHIZOPHRENIC PATIENTS WITH AUD AND SUD (EU study number: OPEL/2020/007) (gennaio 2021-gennaio 2022). PI: Prof. Giovanni Martinotti, Department of Neuroscience, Imaging, and Clinical Science - "G. d'Annunzio" University of Chieti-Pescara, Italy
- Coordinatore per l'Università di Chieti dello studio multicentrico nazionale VESPA (Vortioxetine in the Elderly vs SSRIs: a pragmatic assessment) in collaborazione con diversi centri universitari in Italia (Luglio 2020/Ottobre 2022)

Studi in corso in collaborazione con l'Università G. D'Annunzio di Chieti:

- Partecipazione per l'Università di Chieti come sub-investigatore allo studio nazionale REAL-ESK, studio retrospettivo osservazionale e multicentrico per la valutazione della sicurezza e dell'efficacia di Esketamina (SPRAVATO) per la terapia di pazienti con diagnosi di depressione resistente al trattamento, in collaborazione con vari centri in Italia
- Partecipazione in qualità di sub-investigatore allo studio DDT (Dual Disorder Trial), studio randomizzato sul trattamento di pazienti Schizofrenici in comorbidità con Disturbo da Uso di Sostanze/Alcol mediante l'utilizzo di Lurasidone vs Brexpiprazolo vs Quetiapina. PI: Prof. Giovanni Martinotti, Department of Neuroscience, Imaging, and Clinical Science - "G. d'Annunzio" University of Chieti-Pescara, Italy
- Partecipazione in qualità di sub-investigatore allo studio 'Neurobiological correlates of Alcohol Use Disorder after transcranial Direct Current Stimulation (tDCS) treatment'. PI: Prof. Giovanni Martinotti, Department of Neuroscience, Imaging, and Clinical Science - "G. d'Annunzio" University of Chieti-Pescara, Italy
- Partecipazione in qualità di sub-investigatore allo studio per la validazione della scala DUAL DISORDER RATING SCALE – DDRS . PI: Prof. Giovanni Martinotti, Department of Neuroscience, Imaging, and Clinical Science - "G. d'Annunzio" University of Chieti-Pescara, Italy
- Partecipazione per l'Università di Chieti come sub-investigatore allo studio: Caratterizzazione clinica e psicopatologica e correlati infiammatori e metabolici degli episodi depressivi (Clinical and psychopathological characterization and inflammatory/metabolic correlates of depressive episodes) - SFIDE in collaborazione con diversi centri universitari in Italia. PI: Prof. Gabriele Sani, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168, Roma (IT).
- Partecipazione per l'Università di Chieti allo studio: "Valutazione dell'efficacia dell'intervento psicoeducativo familiare per la depressione maggiore: uno studio randomizzato-controllato". PI: Prof. Andrea Fiorillo, Dipartimento di Psichiatria, Università degli Studi della Campania "Luigi Vanvitelli" (IT)

Febbraio 2017/Maggio 2019

Dirigente Medico Psichiatra

Struttura residenziale psichiatrica accreditata con il Servizio Sanitario Nazionale Villa Rosa- Viterbo (VT), IT
Medico di reparto presso: STPIT (Struttura di Trattamento Psichiatrico Intensivo Territoriale)

Luglio 2018/Marzo 2020

Dirigente Medico Psichiatra presso:

-ASL VT/C: CSM Vignanello (VT), CSM Vetralla (VT);

-ASL RM/1: Casa Circondariale di Regina Coeli, Roma;

-ASL RM/2: CSM Via degli Eucalipti, Roma; Casa Circondariale di Rebibbia, Roma.

Marzo 2017/Settembre 2017

Direttore Sanitario

Struttura Residenziale Socio-Riabilitativa (SRSR)H24 Johnny & Mary- Paliano (FR), IT

Luglio 2016/ Febbraio 2017

Dirigente Medico Psichiatra

Residenza per l'esecuzione delle misure di sicurezza (REMS) Pegaso, Carovigno (BR)

Luglio 2014/Giugno 2016

Medico di guardia

Struttura residenziale psichiatrica accreditata con il Servizio Sanitario Nazionale San Valentino, Roma, IT

Aprile 2013/Novembre 2013
Academic visiting researcher
International Centre for Drug Policy (ICDP), St George's University of London
National Programme on Substance Abuse Deaths (np-SAD): Data entry, analyses (IBM SPSS use and descriptive statistics) and assistance with report writing (*Drug-related deaths in the UK Annual Report 2013*).
Preparation of specialist reports on Methoxetamine and Mephedrone.
Coordinator: Prof. Schifano

Insegnamento

Marzo 2023/ ad oggi

Attività didattica in materia di "Psichiatria" nella Scuola di Specializzazione in Psicoterapie Brevi ad Approccio Strategico, Istituto per lo Studio delle Psicoterapie (ISP), Roma (IT)

Novembre 2022/ad oggi

Titolare a contratto dell'insegnamento di Psichiatria SSD MED/25 n. 30 ore (3) per il Corso di Laurea in Medicina e Chirurgia-IV anno dell'Università UniCamillus, Roma, Italia. Anno Accademico 2022-2023.

Novembre 2022/ad oggi

Titolare a contratto dell'insegnamento di Psichiatria SSD MED/25 n. 14 ore (1) per il Corso di Laurea in Scienze Infermieristiche-III anno dell'Università UniCamillus, Roma, Italia. Anno Accademico 2022-2023.

Novembre 2022/ad oggi

Titolare a contratto dell'insegnamento di Psichiatria SSD MED/25 n. 10 ore (1) per il Corso di Laurea Triennale in Fisioterapia- II anno dell'Università UniCamillus, Roma, Italia. Anno Accademico 2022-2023.

Dicembre 2019/dicembre 2022

Attività didattica in materia di "Neurobiologia delle dipendenze e trattamento psichiatrico e farmacologico" nel Master in Psicologia e Trattamento delle Dipendenze – Istituto per lo Studio delle Psicoterapie (ISP), Roma (IT)

Novembre 2019/gennaio 2023

Attività didattica relativa all'insegnamento di Psichiatria (CFU 2). Corso di Laurea Triennale di Fisioterapia – Università Cattolica del Sacro Cuore – Sede di Villa Immacolata, S. Martino al Cimino (VT), IT

Novembre 2018/gennaio 2019

Attività didattica relativa all'insegnamento di Scienze Infermieristiche-Tecniche Neuro Psichiatriche Riabilitative (CFU 2). Corso di Laurea in Tecnica della Riabilitazione Psichiatrica, Università di Roma 'La Sapienza', sede di Viterbo. Anno Accademico 2018-2019

Dicembre 2017/ Luglio 2022

PhD in Pharmacy, Pharmacology and Postgraduate Medicine

School of Life and Medical Sciences - Allied Health Professions, Dentistry, Nursing and Pharmacy

Department of Clinical, Pharmaceutical and Biological Sciences

University of Hertfordshire, Hatfield, Herts (UK)

Final thesis: *Assessing the extent and characteristics of non-medical use of a range of prescribed drugs: epidemiological and pharmacovigilance approaches*

Luglio 2021

ATOMIC-ADDICTION TO MEDICATION: IMPROVING CARE. Non-medical use of prescription drugs.

Available online: <https://addiction-to-medication.org/atomic/>

Giugno 2021

Pharmacovigilance Training -Modules: Drug Safety, Global Regulatory Requirements Pharmacovigilance, Signalling and

Risk Assessment. Available on line: <https://www.whitehalltraining.com/all-pharmacovigilance-courses>

Aprile 2021

Good Clinical Pharmacovigilance Practice Training.

Available online: <https://www.pharmalessons.com/trainingcampus/course/view.php?id=10>

Aprile 2021

MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA). E-learning module on Adverse Drug Reactions (ADRs). 'Adverse Drug Reactions: reporting makes medicines safer'.

Available online: https://yellowcard.mhra.gov.uk/resources/story_html5.html?lms=1

Formazione

Luglio 2020
Uppsala Monitoring Centre
Introduction to pharmacovigilance (Online course)
Signal detection and causality assessment (Online course)
Statistical reasoning and algorithms in pharmacovigilance (Online course)

Gennaio 2017/Gennaio 2018

Master di II livello

Psicologia forense e criminologia
Università LUMSA, Roma, IT

Tesi in: Il paziente psichiatrico autore di reato nella transizione dagli OPG alle REMS: considerazioni e prospettive.
Voto finale: 110/110 cum laude

Luglio 2011/Giugno 2016

Specializzazione in Psichiatria e Psicoterapia

Policlinico Gemelli-Università Cattolica del Sacro Cuore

Tesi in: *Misuse of pregabalin and gabapentin in the last decade: analysis and assessment of Adverse Drug Reactions (ADR) reported to the European Medicines Agency (EMA)* (in collaborazione con il Prof. Schifano, University of Hertfordshire School of Life and Medical Sciences; Hatfield, Herts-UK)

Voto finale: 50/50 cum laude

Gennaio 2014/ Giugno 2014

The Italian School on Addiction

Dipartimento Politiche Antidroga– Roma, IT

Tesi in: *Dysregulation of reward and dopaminergic transmission in Pathological Gambling: an experimental study using the technic 123I-FP-CIT SPECT*

Ottobre 2011/ Settembre 2012

Corso di primo livello in Psicopatologia Fenomenologica – Firenze, IT

Febbraio 2011

ABILITAZIONE alla Professione Medica

Voto finale: 270/270

Agosto 2010

Department of Neurology - University Medical Centre Ljubljana - Slovenia

Professional Exchange- International Federation of Medical Students Association

Ottobre 2004/Luglio 2010

Laurea in Medicina e Chirurgia – Università Cattolica del Sacro Cuore, Roma, IT

Thesis in Psychiatry: *Psychopathologic aspects of obesity: psychodiagnostic evaluations of bariatric surgery applicants*

Voto finale: 110/110 cum laude

Settembre 2006/Luglio 2007

Erasmus Program

Facultad de Medicina y Cirugía - Universidad De Salamanca – Salamanca, Spain

Settembre 1998 /Luglio 2003

Liceo Classico 'Benedetto Marzolla', Brindisi (BR), IT

Voto finale: 100/100

PERSONAL SKILLS

BLS-D COURSE (marzo 2019).

Lingua madre

Italiano

Altre Lingue

	COMPREHENSION*		SPEAKING*		WRITING*
	LISTENING	READING	ORAL INTERACTION	ORAL PRODUCTION	
English	C1	C1	B2	B2	C1
Spanish	C1	C1	C1	C1	C1
French	B2	B2	B1	B1	B1

(*)Common European Framework of Reference for Languages

Settembre 2017

IELTS Certification: average band 6.5

Luglio 2015/ Ottobre 2015

Course of English, level B2

Scuola Internazionale di Lingue

Via Venti Settembre – Rome, IT

Ottobre 2010

TOEFL test

Mark: 80

Agosto 2004

University of Malta

English course – Level: Upper Intermediate

November 2006

BULATS (ALTE) - Spanish

Level C1/4

Ottobre 2006

Universidad de Salamanca

Spanish Course – Diploma Superior de Espanol

Altre certificazioni

Aprile 2021

R101 An Introduction to R (Electv training)

R102 An Introduction to R (Electv training)

R103 An Introduction to R (Electv training)

Dicembre 2003

ECDL (European Computer Driving Licence)

Base Concepts, File Management, Microsoft Word, Microsoft Excel, Microsoft Access, Microsoft Power Point, Microsoft Internet Explorer 5, Microsoft Outlook Express 5

Altre informazioni

Novembre 2020

Vincitrice della borsa: Post-Graduate Researcher conference funding grant – University of Hertfordshire - UK

Ottobre 2020

Membro della Società Italiana Patologie da Dipendenza-S.I.Pa.D.

Ottobre 2020

Membro della International Society of Substance Use Professionals (ISSUP)

Ottobre 2020

Membro del Network of Early Career Professionals working in the area of Addiction Medicine (NECPAM)

Ottobre 2020
Membro del Young Psychiatrists' Network (YPN)

Febbraio 2015
Travel Grant (supportato da Lilly) per il 17th Congress of the European Society for Sexual Medicine (Copenhagen), per la presentazione: *Hyper sexuality and compulsive behaviors triggered by dopaminergic therapies in a case of Parkinson's Disease*

Aprile 2011
Borsa di Studio "Studenti Meritevoli Regione Abruzzo" - Banca di Lanciano e Sulmona - IT

Dicembre 2004
Borsa di Studio Alfieri del Lavoro - Federazione Nazionale dei Cavalieri del Lavoro- IT

Agosto 2004
Borsa di Studio, Ministero degli Affari Esteri, IT

Publications on peer-reviewed journals

To bridge or not to bridge: Moral Judgement in Cocaine Use Disorders, a case-control study on human morality.
Mosca A, Miuli A, Mancusi G, **Chiappini S**, Stigliano G, De Pasquale A, Di Petta G, Bubbico G, Pasino A, Pettorruso M, Martinotti G.
Social Neuroscience, 2023. <https://doi.org/10.1080/17470919.2023.224209>

An Update on Psychoactive Substances: Pharmacology and Toxicology Issues.
Chiappini S, Schifano F.
Pharmaceuticals. 2023; 16(8):1177. <https://doi.org/10.3390/ph16081177>

Predicting outcome with Intranasal Esketamine treatment: a machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).
Pettorruso M, Guidotti R, d'Andrea G, De Risio L, D'Andrea A, **Chiappini S**, Carullo R, Barlati S, Zanardi R, Rosso G, De Filippis S, Di Nicola M, Andriola I, Marcatili M, Nicolò G, Martiadis V, Bassetti R, Nucifora D, De Fazio P, Rosenblat JD, Clerici M, Dell'Osso BM, Vita A, Marzetti L, Sensi SL, Di Lorenzo G, McIntyre RS, Martinotti G.
Psychiatry Research, available online 28 July 2023, 115378. doi:10.1016/j.psychres.2023.115378.

Efficacy of psychosocial and psychological interventions in addition to drug therapy to improve global functioning of inpatients with schizophrenic spectrum and mood disorders: a real-world observational study.
Chiappini S, Di Carlo F, Mosca A, d'Andrea G, Di Paolo M, Lorenzini C, Lupica MG, Sampogna G, Pettorruso M, Fiorillo A, Martinotti G.
Neuropsychiatr Dis Treat. 2023 Aug 30;19:1887-1897. doi: 10.2147/NDT.S418627

Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
d'Andrea G, **Chiappini S**, McIntyre RS, Stefanelli G, Carullo R, Andriola I, Zanardi R, Martiadis V, Sensi SL, Sani G, Clerici M, Di Lorenzo G, Vita A, Pettorruso M, Martinotti G.
Am J Geriatr Psychiatry. 2023 Jul 8;S1064-7481(23)00351-2. doi: 10.1016/j.jagp.2023.06.016.

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.
Chiappini S, Vickers-Smith R, Harris D, Papanti Pelletier GD, Corkery JM, Guirguis A, Martinotti G, Sensi SL, Schifano F.
Pharmaceuticals 2023, 16, 994. <https://doi.org/10.3390/ph16070994>

Aripiprazole once monthly as a maintenance treatment for patients with schizophrenia and alcohol/substance use disorder: an observational, real-world study.
Chiappini S, Mosca A, Miuli A, Di Carlo F, d'Andrea G, Napolitano A, Santangelo M, Esposito C, Rosazza A, Haefele E, Di Petta G, Pettorruso M, Sensi SL, Martinotti G.

Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study

Chiappini S, d'Andrea G, De Filippis S, Di Nicola M, Andriola I, Bassetti R, Barlati S, Pettorruso M, Clerici M, Dell'Osso B, Vita A, Martinotti G.

Eur Neuropsychopharmacol. 2023 May 4;74:15-21. doi: 10.1016/j.euroneuro.2023.04.011.

Treating Bipolar Depression with Esketamine: safety and effectiveness in bipolar versus unipolar treatment-resistant depression

Martinotti G, Dell'Osso B, Di Lorenzo G, Maina G, Bertolino A, Clerici M, Barlati S, Rosso G, Di Nicola M, Marcatili M, d'Andrea G*, Cavallotto C, **Chiappini S**, De Filippis S, Nicolò G, De Fazio P, Andriola I, Zanardi R, Nucifora D, Di Mauro S, Bassetti R, Pettorruso M, McIntyre RS, Sensi SL, di Giannantonio M, Vita A, and the REAL-ESK Study Group

Bipolar Disord. 2023 Jan 13. doi: 10.1111/bdi.13296.

Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study).

Martinotti G, Vita A, Fagiolini A, Maina G, Bertolino A, Dell'Osso B, Siracusano A, Clerici M, Bellomo A, Sani G, d'Andrea G, Delle Chiaie R, Conca A, Barlati S, Di Lorenzo G, De Fazio P, De Filippis S, Nicolò G, Rosso G, Valchera A, Nucifora D, Di Mauro S, Bassetti R, Martiadis V, Olivola M, Belletti S, Andriola I, Di Nicola M, Pettorruso M, McIntyre RS, di Giannantonio M, the REAL-ESK Study Group REAL-ESK [Baldacci G (Department of Mental Health and Addiction Services, Niguarda Hospital, Milan and Department of Mental Health and Addiction Services, Spedali Civili Hospital, Brescia, Italy), Benatti B (Department of Biomedical and Clinical Sciences Luigi Sacco University of Milan, Italy), Simone Bolognesi (University of Siena, Italy), Bufi I (Università degli Studi di Bari "Aldo Moro", Italy), Carullo R (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), **Chiappini S** (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), Collevicchio R (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), Colmegna F (Dipartimento di Salute Mentale e Dipendenze ASST Monza, Italy), de Berardis D (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), di Carlo F (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), di Natale C (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), Giorgelli V (Università degli Studi di Bari "Aldo Moro", Italy), Arianna Goracci (University of Siena, Italy), Lombardozi G (Neuropsychiatric Clinic, Villa Von Siebenthal, Rome, Italy), Marcatili M (Dipartimento di Salute Mentale e Dipendenze ASST Monza, Italy), Chiara Mattei (Psychiatric Service of the Health District of Bozen, Italy), Mosca A (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), Niolu C (University of Rome Tor Vergata, Italy), Percudani M (Department of Mental Health and Addiction Services, Niguarda Hospital, Milan, Italy), Pepe M (Università Cattolica del Sacro Cuore, Rome, Italy), Rossi E (Neuropsychiatric Clinic, Villa Von Siebenthal, Rome, Italy), Scardigli MI (Department of Mental Health and Addiction, ASL Roma5, Rome, Italy), Tatì F (MDSMA Taormina-Messina Sud ASP di Messina, Italy), Vigano C (Department of Biomedical and Clinical Sciences Luigi Sacco University of Milan, Italy), Ventriglio A (Department of Clinical and Experimental Medicine, University of Foggia, Italy), Vismara M (Department of Biomedical and Clinical Sciences Luigi Sacco University of Milan, Italy)].

J Affect Disord. 2022 Dec 15;319:646-654. doi: 10.1016/j.jad.2022.09.043

Editorial: [Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction-Volume II]

Chiappini S, Schifano F, Martinotti G.

Frontiers in Psychiatry 2022. doi: 10.3389/fpsy.2022.1053896

Evaluating craving in Alcohol Use Disorder: psychometric characteristics of the Craving Typology Questionnaire-15 (CTQ-15).

Martinotti G, Festa G, Ceci F, Callea A, Capparelli A, Bonifaci L, Chillemi E, Pettorruso M, **Chiappini S**, Di Nicola M, Janiri L.

Alcohol Alcohol. 2023 Mar 10;58(2):142-150. doi: 10.1093/alcalc/agac051.

Ibogaine/Noribogaine in the treatment of Substance Use Disorders: a systematic review and Meta-analysis of side effects

Mosca A, **Chiappini S**, Miuli A, Mancusi G, Santovito MC, Di Carlo F, Pettorruso M, Corkery JM, Canessa C, Martinotti G, Di Giannantonio M

Curr Neuropharmacol. 2022 Oct 17. doi: 10.2174/1570159X21666221017085612

Recreational drug misuse and its potential contribution to male fertility levels' decline: a narrative review
Schifano N*, **Chiappini S***, Mosca A, Miuli A, Santovito MC, Martinotti G, Pettorruso M, Salonia A, Di Giannantonio M,
Schifano F

*These authors contributed equally to this work

Brain Sci. 2022, 12(11), 1582; <https://doi.org/10.3390/brainsci12111582>

Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases

Salonia A, Capogrosso P, Boeri L, **Chiappini S**, Schifano N, Cakir O, Rewhorn M, Castiglione F, Alnajjar H, Muneer A, Dehò F, Schifano F, Montorsi F, Fallara G, Harvey H.

Int J Impot Res. 2022 May 5. doi: 10.1038/s41443-022-00568-2.

High-risk gaming is associated with frequent substance use: an exploratory survey among young adults.

Di Carlo F, Verrastro V, Alessi MC, Sociali A, Altomare AI, Di Natale C, Stigliano G, Miuli A, Lalli A, Di Petta G, **Chiappini S**, Pettorruso M, Bowden-Jones H, Griffiths M, Martinotti G.

European Addiction Research. Eur Addict Res 2023;29:241–252, doi: 10.1159/000529544.

Pharmacovigilance signals of the opioid epidemic over 10 years: an analysis of pharmacovigilance datasets collecting Adverse Drug Reactions (ADRs) reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)

Chiappini S, Vickers-Smith R, Guirguis A, Corkery JM, Martinotti G, Schifano F.

Pharmaceuticals (Basel). 2022 May 27;15(6):675. doi: 10.3390/ph15060675.

Climate change, biodiversity loss and mental health: A global perspective.

Cianconi P, Hirsch D, **Chiappini S**, Martinotti G, Janiri L.

BJPsych International, 1-4. doi:10.1192/bji.2022.20

Knowledge and use of over-the-counter drugs in Italy: a survey-based study in the general population

Chiappini S, Ceci F, Mosca A, Di Carlo F, Burkauskas J, Pettorruso M, Martinotti G, Guirguis A, Corkery JM; Scherbaum N, Schifano F, Di Giannantonio M.

Curr Neuropharmacol. 2023;21(1):133-141. doi: 10.2174/1570159X20666220714104231.

Misuse of anticholinergic medications: a systematic review.

Chiappini S, Mosca A, Miuli A, Semeraro F, Mancusi G, Santovito MC, Di Carlo F, Pettorruso M, Guirguis A, Corkery JM; Martinotti G, Schifano F, Di Giannantonio M.

Biomedicines. 2022 Feb 1;10(2):355. doi: 10.3390/biomedicines10020355.

Alprazolam-related deaths in Scotland, 2004-2020

Corkery J, Guirguis A, **Chiappini S**, Martinotti G, Schifano F.

J Psychopharmacol. 2022 Sep;36(9):1020-1035. doi: 10.1177/02698811221104065.

Atypical antipsychotic drugs in dual disorders: current evidence and clinical guidelines.

Martinotti G, **Chiappini S**, Mosca A, Miuli A, Santovito MC, Pettorruso M, Skryabin V, Sensi SL, Di Giannantonio M.

Current Pharmaceutical Design 2022;28(27):2241-2259.

A focus on abuse/misuse and withdrawal issues with selective serotonin reuptake inhibitors (SSRIS): Analysis of both the European EMA and the US FAERS pharmacovigilance databases.

Chiappini S, Vickers-Smith R, Guirguis A, Corkery JM, Martinotti G, Schifano F.

Pharmaceuticals (Basel). 2022 May 1;15(5):565. doi: 10.3390/ph15050565.

Duration of Untreated Disorder and Cannabis Use: an observational study on a cohort of young Italian patients experiencing psychotic experiences and dissociative symptoms

Ricci V, Martinotti G, Ceci F, **Chiappini S**, Di Carlo F, Burkauskas J, Susini O, Luciani D, Quattrone D, De Berardis D, Pettorruso M, Maina G, Di Giannantonio M.

Int J Environ Res Public Health. 2021 Nov 30;18(23):12632. doi: 10.3390/ijerph182312632

Efficacy of Non-Invasive Brain Stimulation on Borderline Personality Disorder core symptoms: a systematic review.
Chiappini S, Picutti E, Alessi MC, Di Carlo F, D'Andrea G, Miuli A, Pettorruso M, Martinotti G, Di Giannantonio M.
J Pers Disord. 2022 Oct;36(5):505-526. doi: 10.1521/pedi.2022.36.5.505.

Medications mostly associated with priapism events: assessment of the 2015-2020 Food And Drug Administration (FDA) pharmacovigilance database entries
Schifano N, Capogrosso P, Boeri L, **Chiappini S**, Pozzivi E, Belladelli F, Onur Cakir O, Rewhorn M, Castiglione F, Alnajjar HM, Muneer A, Deho' F, Schifano F, Montorsi F, Salonia A.
Journal of Urology, 2021, 206(3): e535.

Drugs associated the most with male-factor infertility: assessment of the 2010-2020 Food And Drug Administration (FDA) pharmacovigilance database
Schifano N, Capogrosso P, Boeri L, **Chiappini S**, Pozzivi E, Belladelli F, Onur Cakir O, Rewhorn M, Castiglione F, Alnajjar HM, Muneer A, Deho' F, Schifano F, Montorsi F, Salonia A.
Journal of Urology, 2021, 206(3): e529.

Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature
Martinotti G, **Chiappini S**, Pettorruso M, Mosca A, Miuli A, Di Carlo F, D'Andrea G, Collevocchio R, Di Muzio I, Sensi SL, Di Giannantonio M.
Brain Sciences, 2021 Jun 27;11(7):856. doi: 10.3390/brainsci11070856.

Club drugs and psychiatric sequelae: an issue of vulnerability and previous psychiatric history
Martinotti G, Merino del Villar C, Garcia Cordoba A, Tubau LA, Castro Sánchez L, Di Carlo F, **Chiappini S**, Pettorruso M, Schifano F, Di Giannantonio M.
Int J Environ Res Public Health 2021, 18, 6944. doi:10.3390/ijerph1813694.

New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature
Chiappini S, Mosca A, Miuli A, Santovito MC, Orsolini L, Corkery JM, Guirguis A, Pettorruso M, Di Giannantonio M, Martinotti G, Schifano F.
Medicina 2021, 57(6), 580; doi:10.3390/medicina57060580 .

Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants.
Schifano F, **Chiappini S**, Miuli A, Mosca A, Santovito MC, Corkery JM, Guirguis A, Pettorruso M, Di Giannantonio M, Martinotti G
Front. Psychiatry 2021; 12:657397. doi: 10.3389/fpsyt.2021.657397.

Editorial: Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction.
Chiappini S, Schifano F, Martinotti G.
Front. Psychiatry 2021;12:688434. doi: 10.3389/fpsyt.2021.688434.

The e-psychoactive drugs' psychopharmacology.
Schifano F, **Chiappini S**, Corkery JM, Guirguis A, Scherbaum N.
Curr Opin Pharmacology, 2021, 57: 165-174. Doi: 10.1016/j.coph.2021.02.008.

New Psychoactive Substances (NPS) and Serotonin Syndrome onset: a Systematic Review.
Schifano, **Chiappini S**, Miuli A, Corkery JM, Scherbaum N, Napoletano F, Arillotta D, Zangani C, Catalani V, Vento A, Pettorruso M, Martinotti G, di Giannantonio M, Guirguis A.
Exp Neurol. 2021 Feb 8;113638. doi: 10.1016/j.expneurol.2021.113638.

Opioid painkillers' dependence in a sample of elderly medical inpatients.
Chiappini S, Schifano F, Martinotti G, Strasser J, Bonnet U, Scherbaum N.
Psychogeriatrics 2021; 21: 265–271. doi: 10.1111/psyg.12658.

The benzydamine experience: a systematic review of benzydamine abuse.

Chiappini S, Miuli A, Mosca A, Pettoroso M, Guirguis A, Corkery JM, Martinotti G, Di Giannantonio M, Schifano F. *Curr. Neuropharmacol.* 2021 Oct 18;19(10):1728-1737. doi: 10.2174/1570159X19666210113151136.

Understanding the use of prescription and OTC drugs in obtaining highs and the pharmacist role in preventing abuse.

Chiappini S, Guirguis A, Corkery J, Schifano F.

Top one research article 2020

The Pharmaceutical Journal Vol.305, No 7943, online (<https://www.pharmaceutical-journal.com/research/perspective-article/misuse-of-prescription-and-over-the-counter-drugs-to-obtain-illicit-highs-how-pharmacists-can-prevent-abuse/20208538.article?firstPass=false>) doi: 10.1211/PJ.2020.20208538.

What about 'pharming'? Issues regarding the misuse/abuse of prescription and over-the-counter drugs.

Chiappini S, Schifano F.

Brain Sci. 2020 Oct; 10(10): 736. doi: 10.3390/brainsci10100736.

Beyond the PURPLE DRANK. Study of promethazine abuse according to the European Medicines Agency (EMA) Adverse Drug Reactions (ADR) reports.

Chiappini S, Schifano F, Corkery JM, Guirguis A.

J Psychopharmacology, 2021 Jun;35(6):681-692. doi: 10.1177/0269881120959615.

Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports.

Schifano N, **Chiappini S**, Castiglione F, Salonia A, Schifano F.

Low Urin Tract Symptoms. 2021 Apr;13(2):230-237. doi: 10.1111/luts.12355.

COVID-19: The hidden impact on mental health and drug addiction.

Chiappini S, Guirguis A, John A, Corkery JM, Schifano F.

Front Psychiatry. 2020; 11: 767. Doi:10.3389/fpsyt.2020.00767.

'Z-trip'? A comprehensive overview and a case-series of Zolpidem misuse.

Orsolini L, **Chiappini S**, Grandinetti P, Bruschi A, Testa R, Provenzano A, De Berardis D.

Clin Psychopharmacol Neurosci. 2021 May 31;19(2):367-387. doi: 10.9758/cpn.2021.19.2.367.

How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy

Orsolini L, **Chiappini S**, De Berardis D, Papanti DG, Tomasetti C, Fornaro M, Vellante F, Latini R, Volpe U.

Hum Psychopharmacol Clin Exp. 2020;e2728.

Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database.

Chiappini S, Schifano F, Corkery JM, Guirguis A.

Brain Sci. 2020, 10(2), 105. doi:10.3390/brainsci10020105.

New/Designer Benzodiazepines': an analysis of the literature and psychonauts' trip reports'.

Orsolini L, Papanti D, Vento A, **Chiappini S**, Guirguis A, Corkery JM, Schifano F.

Curr Neuropharmacol. 2020 Jan 10. doi: 10.2174/1570159X18666200110121333.

The bridge between classical and 'synthetic'/chemical psychoses: towards a clinical, psychopathological and therapeutic perspective.

Orsolini L, **Chiappini S**, Papanti D, De Berardis D, Corkery JM, Schifano F.

Front. Psychiatry. 2019 Nov 20;10:851. Doi: 10.3389/fpsyt.2019.00851.

The role of novel psychoactive substances (NPS) in mental health care of young people; a systematic review.

Orsolini L, **Chiappini S**, Corkery JM, Guirguis A, Papanti D, Schifano F.

Expert reviews of neurotherapeutics. 2019 Sep 24:1-12. doi: 10.1080/14737175.2019.1666712.

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. Orsolini L, **Chiappini S**, Volpe U, De Berardis D, Latini R, Papanti GD, Corkery JM. *Medicina*. 2019, 55, 525; doi:10.3390/medicina55090525.

Cannabidiol (CBD) Use in Psychiatric Disorders: a Systematic Review. Bonaccorso S, Ricciardi A, Zangani C, **Chiappini S**, Schifano F. *Neurotoxicology*. 2019 Sep;74:282-298. doi: 10.1016/j.neuro.2019.08.002.

New/emerging psychoactive substances and associated psychopathological consequences. Schifano F, Napoletano F, **Chiappini S**, Guirguis A, Corkery JM, Bonaccorso S, Ricciardi A, Scherbaum N, Vento A. *Psychological Medicine* 2019; 1–13. doi:10.1017/S0033291719001727.

New psychoactive substances (NPS), psychedelic experiences, and dissociation; clinical and clinical pharmacological issues. Schifano F, Napoletano F, **Chiappini S**, Orsolini L, Guirguis A, Corkery JM, Bonaccorso S, Ricciardi A, Scherbaum N, Vento A. *Current Addiction Reports* (2019) 6:140–152. doi: 10.1007/s40429-019-00249-z.

Pregabalin: a range of misuse-related unanswered questions. Schifano F, **Chiappini S**. *CNS Neurosci Ther*. 2019 May;25(5):659-660. doi: 10.1111/cns.13115.

An insight into Z-drugs abuse and dependence: an examination of reports to the European Medicines Agency (EMA) database of suspected Adverse Drug Reactions (ADR). Schifano F, **Chiappini S**, Corkery JM, Guirguis A. *Int J Neuropsychopharmacol*. 2019 Apr 1;22(4):270-277. doi: 10.1093/ijnp/pyz007.

Assessing The 2004–2018 Fentanyl Misusing Issues Reported To An International Range Of Adverse Reporting Systems **Chiappini S**, Schifano F, Guirguis A, Corkery JM. *Front. Pharmacol*. 2019; 10:46. doi: 10.3389/fphar.2019.00046.

Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports. Schifano F, **Chiappini S**. *PLoS ONE* 2018; 13(10): e0204443. doi: 10.1371/journal.pone.0204443.

Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review Schifano F, **Chiappini S**, Corkery J, Guirguis A. *Editor's Choice Article* *Brain Sci*. 2018, 8(4), 73. doi:10.3390/brainsci8040073.

There is a potential of misuse for venlafaxine and bupropion? Schifano F, **Chiappini S**. *Front. Pharmacol*. 2018; 9:239. doi: 10.3389/fphar.2018.0023921.

β-2 agonists as misusing Drugs? Assessment of both Clenbuterol- and Salbutamol-related European Medicines Agency (EMA) Pharmacovigilance Database Reports. Milano G, **Chiappini S**, Mattioli F, Martelli A, Schifano F. *Basic Clin Pharmacol Toxicol*. 2018 Mar 2. doi: 10.1111/bcpt.12991.

Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database. **Chiappini S**, Schifano F. *J Clin Psychopharmacol*. 2018 Feb;38(1):72-79. doi: 10.1097/JCP.0000000000000814.

- A decade of gabapentinoid misuse: an analysis of the European Medicines Agency's 'suspected adverse drug reactions' database. Assessment of gabapentinoid misuse/dependence as reported to the EMA.
Chiappini S, Schifano F.
CNS drugs 2016, 30,5: 1-8. doi: 10.1007/s40263-016-0359-y.
- Compulsiveness dimension in a case of Pathological Gambling.
Chiappini S, Testa R, Di Paolo M, Leone B, Maisto F, Pascucci M, Grandinetti P, Polidori F, Conte G.
European Psychiatry 33S (2016) S353-354.
- Deaths of individuals aged 16–24 years in the UK after using mephedrone.
Loi B, Corkery JM, Claridge H, Goodair C, **Chiappini S**, Gimeno Clemente C, Schifano F.
Hum Psychopharmacol Clin Exp 2015; 30(4):225-232.
- Methoxetamine-related deaths in the UK: an overview .
Chiappini S, Claridge H, Corkery JM, Goodair C, Loi B, Schifano F.
Hum Psychopharmacol Clin Exp 2015; 30: 244–248
- Age in Pathological Gambling: Correlations with Personality and Psychiatric Comorbidity.
Pascucci M, Pettorruso M, Vilella C, Righino E, Ciciarelli C, **Chiappini S**, Di Cesare A, Testa R, Di Paolo M, Janiri L, Conte G.
European Psychiatry 2015, 30, Supplement 1, 28–31: 499.
- Online Gambling, Impulsivity and Personality Traits: an Italian Sample.
Pascucci M, **Chiappini S**, Vilella C, Righino E, Pettorruso M, Ciciarelli C, Di Cesare A, Testa R, Di Paolo M, Janiri L, Conte G.
European Psychiatry 2015, 30, Supplement 1, 28–31: 1086.
- Validation of a diagnostic questionnaire based on DSM-IV criteria for gambling.
Sabetta L, Di Paolo M, Testa R, **Chiappini S**, Pettorruso M, Di Cesare A, Vilella C, Conte GL.
European Psychiatry 2013, 28, Supplement 1, 1.
- Glutamatergic strategies in the treatment of pathological gambling: a pilot study.
Pettorruso M, Conte G, Righino E, Di Cesare A, **Chiappini S**, Testa R, Janiri L.
European Psychiatry 2013, 28, Supplement 1, 1.
- Behavioural changes in cocaine dependent patients after group-therapy
Di Paolo M, **Chiappini S**, Testa R, Pettorruso M, Di Cesare A, Sabetta L, Conte GL.
European Psychiatry 2013, 28, Supplement 1, 1.
- Relationship between impulsivity, mood disorders and personality traits in a sample of pathological gamblers.
Righino E, Pascucci M, Pettorruso M, Ciciarelli C, Di Cesare A, **Chiappini S**, Giallonardo V, Vilella C, Conte GL.
European Psychiatry 2012, 27, Supplement 1, 1.
- Evaluation of an italian sample of gamblers with dannon ainhold gambling scale: preliminary study
Pascucci M, Pettorruso M, Righino E, Vilella C, Ciciarelli C, Di Cesare A, **Chiappini S**, Testa R, Conte GL, Dannon PN.
European Psychiatry 2012, 27, Supplement 1, 1.
- Psychosocial risk factors for postpartum depression: a descriptive sample of pregnant.
Chiappini S, D'Oria L, Righino E, Bruschi A, Di Nardo D, Oliva G, Janiri L.
European Psychiatry 2012, 27, Supplement 1, 1
- Psychopathologic aspects of obesity: psychodiagnostic evaluations of bariatric surgery applicants.
Chiappini S, Righino E, Ciciarelli C, Pettorruso M, Conte GL.

European Psychiatry 2011, 26, 714.

Publications on non peer-reviewed journals

[Trazodone Contramid® nel paziente depresso con abuso di alcol] Article in Italian.

Dattoli L, **Chiappini S**.

Esperienze cliniche in Psichiatria. Suppl. 2/2023, pag.14-15.

[Lurasidone as a new therapeutic approach for the treatment of double diagnoses: a case report] Article in Italian.

Chiappini S, Dattoli L, Martinotti G.

Evidence-based Psychiatric Care 2023;9(1 Suppl 1):7-8; <https://doi.org/10.36180/2421-4469-2023-S4>

Brexpiprazole as an augmentation agent to a selective serotonin reuptake inhibitor (SSRI) in the treatment of a case of somatization disorder

Chiappini S, Mosca A, Martinotti G, Di Carlo F, Miuli A, Dattoli L, Pettorruso M, Di Giannantonio M.

Emerg Trends Drugs Addict Health 2022: 100031

Special M related fatalities in the UK.

Chiappini S, Claridge H, Corkery J, Goodair C, Loi B, Schifano F.

Research and Advances in Psychiatry 2014;1(Suppl. 1):38.

Methoxetamine: An Analogue of Ketamine.

Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Loi B, Schifano F.

Current Drug Abuse Reviews, 2013, 6: 84-5.

Fatalities Associated with Mephedrone in Combination with Other Stimulant Drugs in Young People Aged 16-24 Years.

Loi B, **Chiappini S**, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Schifano F.

Current Drug Abuse Reviews, 2013, 6: 292-3.

The Unregulated Psychoactive Compound: 'Benzo Fury'.

Gimeno Clemente C, **Chiappini S**, Claridge H, Corkery J, Goodair C, Loi B, Schifano F.

Current Drug Abuse Reviews, 2013, 6: 286.

Before the treatment of Gambling: how personality characteristics influence access to our service?

Conte GL, Ciciarelli C, Di Cesare A, **Chiappini S**, Testa R, Martinotti G, Janiri L.

Italian Journal of Addiction, 2012, 2, 3-4.

A doubtful case of dyskinesia: a psychogenic movement disorder, a consequence of a psychopharmacological therapy, or both?

Testa R, **Chiappini S**, Okulska J, Di Cesare A, Pettorruso M, Conte G.

L'altro-2012, n.2 Maggio-Agosto.

Psychometric tests and risk factors for screening of mood disorders in pregnancy and post-partum: a preliminary study.

D'oria L, Leggieri C, Chiappini S, Janiri L, Oliva G.

Italian Journal of Gynaecology and Obstetrics, 2012 9-17 (9).

A Rorschach test study on the personality characteristics of a sample of pathological gamblers compared to healthy controls.

Villella C, Di Gioia A, Martinotti G, Pomponi M, Righino E, Ciciarelli C, Pettorruso M, Di Cesare A, Pascucci M, **Chiappini S**, Conte G.

Dipendenze patologiche 2011; 1:19-22.

Chapters

[Le nuove sostanze psicoattive] (IT)

Martinotti G, **Chiappini S**, Santacroce R, Cinosi E, Schifano F, di Giannantonio M

In *Manuale di Psichiatria* edited by Siracusano A. Il Pensiero Scientifico Editore (2022).

NPS Stimulants

Schifano F, Corkery JM, Catalani V, **Chiappini S**, Arillotta D, Vento A, Scherbaum N, Guirguis A

In *New psychoactive substances. Challenges, consequences and treatment approaches* edited by Kristina Adorjan, Sharon Walsh and Thomas G. Schulze. Oxford University Press (2021).

Psychobiological; medical; and psychiatric implications of new/novel psychoactive substance (NPS) use.

Schifano F, **Chiappini S**, Catalani V, Napoletano F, Arillotta D, Zangani C, Guirguis A, Vento AE, Bonaccorso S, Corkery JM. Chapter 11 (pp. 213-233) in Murphy, P. (ed.). *Psychobiological Issues in Substance Use and Misuse*. Routledge.

<https://books.google.co.uk/books?hl=en&lr=&id=mQPEAAQBAJ&oi=fnd&pg=PT212&ots=9x3DvDxNag&sig=jFMMvfi1BAHKIMZtjMGqjJDPEE#v=onepage&q&f=false>

ISBN hardback: 978-0-367-27360-6; ISBN paperback: 978-0-367-27361-3; ISBN e-book: 978-0-429-29634-5 (2021).

[Nuove frontiere nell'abuso di sostanze, psiconauti e internet] (IT)

Zangani C, **Chiappini S**, Napoletano F, Orsolini L, Schifano F.

In *Prevenzione, giovani e... come investire nella formazione scolastica per la salute*, Modonutti GB. Edizioni Goliardiche (2020).

[NUOVE SOSTANZE PSICOATTIVE] (IT)

Santacroce R, Martinotti G, **Chiappini S**, Schifano F.

In *Compendio di Psicopatologia*, edited by Martinotti G, Di Giannantonio M, Janiri L. Ed. fila 37 (2019)..

Substance-Use Disorders and Violence

Schifano F, Zangani C, **Chiappini S**, Guirguis A, Bonaccorso S, Corkery J.

Series Title: Comprehensive Approach to Psychiatry In *Violence and Mental Disorders* (2019).

[Cannabis: evidenze epidemiologiche, cliniche e terapeutiche] (IT)

Chiappini S, Schifano F.

In *UNOSUQUATTRO. Diffusione e significati del consumo di cannabinoidi tra gli adolescenti: una questione educativa* edited by Iori V, Gianotti F. Franco Angeli Editore (2019).

EMCDDA. Mini guide on the non-medical use of medicines: health and social responses 2021.

https://www.emcdda.europa.eu/publications/mini-guides/non-medical-use-of-medicines-health-and-social-responses_en

Drug-related deaths in the UK Annual Report 2013

Ghodse H, Corkery J, Claridge H, Goodair C, Schifano F.

Riconoscimenti

Giugno 2023

Percorsi 2023

Gestione dei pazienti con depressione resistente al trattamento in comorbidità con il disturbo da uso di sostanze: sicurezza ed efficacia dell'esketamina in un sottocampione di pazienti dello studio REAL-ESK.

Chiappini S; d'Andrea G; Cavallotto C; Mosca A; Dattoli L; Sensi S; Pettorruso M; Martinotti G; REAL-ESK study group

Ottobre 2022

SIP 2022

The opioid epidemic over the past 10 years: pharmacovigilance signals from the European Medicines Agency (EMA) and the FDA Adverse Event Reporting System (FAERS)

Chiappini S, Mosca A, Guirguis A, Corkery JM, Di Giannantonio M, Martinotti G, Schifano F.

Poster presentations

Ottobre 2022

SIP 2022

A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): An Analysis of Pharmacovigilance Databases

Chiappini S, Guirguis A, Corkery JM, Martinotti G, Schifano F.

Giugno 2022

Life and Medical Science Conference- University of Hertfordshire, Hatfield (UK)

A Focus On Abuse/Misuse And Withdrawal Issues With Selective Serotonin Reuptake Inhibitors (SsrIs): An Analysis Of Pharmacovigilance Databases

Chiappini S, Guirguis A, Corkery JM, Schifano F.

Giugno 2022

Life and Medical Science Conference- University of Hertfordshire, Hatfield (UK)

Alprazolam-Related Deaths in Scotland, 2004-2020

Corkery, JM, Guirguis A, Chiappini S, Martinotti G, Schifano F.

Giugno 2021

Life and Medical Science Conference- University of Hertfordshire, Hatfield (UK)

The benzydamine experience: an analysis of benzydamine related data from the European Monitoring Agency (EMA) Adverse Drug Reactions (ADR) database.

Chiappini S, Miuli A, Mosca A, Guirguis A, Corkery JM, Martinotti G, Schifano F.

Giugno 2020

RPS Science & Research Summit-London (UK)

The misuse of prescription drugs in the digital era: pros and cons.

Chiappini S, Guirguis A, Corkery JM, Schifano F.

Novembre 2020

VII New Psychoactive Substances conference- online ed.

BEYOND THE PURPLE DRANK. STUDY OF PROMETHAZINE ABUSE ACCORDING TO THE EUDRAVIGILANCE DATASET.

Chiappini S, Schifano F, Corkery JM, Guirguis A.

Novembre 2019

Royal Pharmacology Society Annual Conference, London (UK)

ARE Z-DRUGS SAFE? STUDY OF THEIR MISUSE, ABUSE AND DEPENDENCE ACCORDING TO THE EUROPEAN MEDICINES AGENCY (EMA) PHARMACOVIGILANCE DATABASE.

Chiappini S, Guirguis A, Corkery J, Schifano F.

Aprile 2019

NPS conference- Maastricht (NL)

Loperamide diversion and abuse: assessment of its non-medical use through the analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports.

Chiappini S, Corkery, JM, Guirguis, A, Schifano F.

Aprile 2019

Life and Medical School Research Conference, University of Hertfordshire, Hatfield, UK.

The uncontrollable rise of opioids. Study of the European situation from the EudraVigilance adverse drug reactions database of fentanyl abuse/misuse/ dependence cases.

Chiappini S, Schifano F, Corkery JM, Guirguis A.

Giugno 2018

School of Health and Social Work Annual Research Conference 2018- University of Hertfordshire, Hatfield, UK

Prescription drug diversion and misuse. Assessment of the non-medical use of a range of molecules through pharmacovigilance databases.

Chiappini S, Corkery, JM, Guirguis, A, Schifano F.

Aprile 2018

Life and Medical School Research Conference, University of Hertfordshire, Hatfield, UK

Analysis of European Monitoring Agency (EMA) EudraVigilance Adverse Drug Reactions database; a pharmacovigilance approach to the study of prescription drug misuse in the context of the Novel Psychoactive Substances (NPS) phenomenon.

Chiappini S, Schifano F, Corkery JM, Guirguis, A.

Maggio 2016

IV National Meeting of Young Psychiatrist-Rome (IT)

Hedonic tone dysfunctions and Dopamine Transporter Availability in Gambling Disorder: Preliminary data from a 123I-FP-CIT SPECT study

Pettoruso M, Di Nicola M, Chiappini S, Conte E, Romano B, Di Giuda D, Tascone E, Curcio E, Cocciolillo F, Giordano A, Conte G, Janiri L

Marzo 2016

European Psychiatric Association (EPA) Congress, Madrid (Spain)
Compulsiveness dimension in a case of Pathological Gambling
Chiappini S, Testa R, Di Paolo M, Leone B, Maisto F, Pascucci M, Grandinetti P, Polidori F, Conte G.

Marzo 2015

European Psychiatric Association (EPA) Congress, Vien (Austria)
Age in Gambling: correlations with personality and psychiatric comorbidity.
M. Pascucci, M. Pettoruso, C. Villella, E. Righino, C. Ciciarelli, S. Chiappini, A. Di Cesare, R. Testa, L. Janiri, G. Conte

Marzo 2015

European Psychiatric Association (EPA) Congress, Vien (Austria)
Online gambling, impulsivity and personality traits: an Italian Sample.
Pascucci M, Chiappini S, Villella C, Righino E, Pettoruso M, Ciciarelli C, Di Cesare A, Testa R, Janiri L, Conte G.

Febbraio 2015

17th Congress of the European Society for Sexual Medicine, Copenhagen (Denmark)
Hyper sexuality and compulsive behaviors triggered by dopaminergic therapies in a case of Parkinson's Disease.
(awarded to receive a Travel Grant supported by Lilly)
[Available online at:
http://www.essm.org/fileadmin/user_upload/medien/dokumente/Cases_that_Matter/04_2015/Chiappini_Case.pdf]

Settembre 2014

XVI World congress of Psychiatry, Madrid (Spain)
Behavioural Addictions In Adolescence: Findings From An Italian Survey
Di Nicola M, Chiappini S, Grandinetti P, De Vita O, Pettoruso M, Conte G, Janiri L.

Settembre 2014

XVI World congress of Psychiatry, Madrid (Spain)
Validation of a new Gambling Questionnaire based on DSM-IV-TR Criteria
Pascucci M, Villella C, De Waure C, Righino E, Ciciarelli C, Pettoruso M, Di Cesare A, Chiappini S, Janiri L, Bria P, Conte G.

Maggio 2014

Third Novel Psychoactive Substances Conference, Rome (Italy)
'Special M' related fatalities in the UK
Chiappini S, Claridge H, Corkery J, Goodair C, Loi B, Schifano F.
(Prize best poster)

Maggio 2014

Third Novel Psychoactive Substances Conference, Rome (Italy)
Gabapentinoids' misuse issues
Schifano F, Chiappini S

Maggio 2014

American Psychiatric Association's 167th Annual Meeting, New York (USA)
A multidisciplinary approach for addiction treatment in an Italian day hospital service: a therapy model and its goals.
Chiappini S, Testa R, Di Paolo M, Grandinetti P, Hatzigiakoumis DS, Conte G

Maggio 2014

American Psychiatric Association's 167th Annual Meeting, New York (USA)
Pregabalin treatment in pathological gambling: a preliminary study
Testa R, Pettoruso M, Di Nicola M, Martinotti G, Di Paolo M, Di Cesare A, Chiappini S, Conte G, Janiri L

Novembre 2013

Society for Study of Addiction Annual Symposium, York (UK)
Methoxetamine: an analogue of Ketamine.
Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Loi B, Schifano F.

Settembre 2013

XI Congresso Società Italiana di Psichiatria Biologica, Naples (Italy)
Utilizzo del pregabalin nel trattamento del gioco d'azzardo patologico: dati preliminari
Pettoruso M, Di Nicola M, Martinotti G, Sabetta L, Di Cesare A, Chiappini S, Testa R, Conte G, Janiri L.

Settembre 2013

Second International Conference on Novel Psychoactive substances, Swansea (UK)

Methoxetamine: an analogue of Ketamine

Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Loi B, Schifano F

Settembre 2013

Second International Conference on Novel Psychoactive substances, Swansea (UK)

The unregulated psychoactive compound 'Benzo Fury'

Gimeno Clemente C, Chiappini S, Claridge H, Corkery J, Goodair C, Loi B, Schifano F

Settembre 2013

Second International Conference on Novel Psychoactive substances, Swansea (UK)

Fatalities associated with Mephedrone in combination with other stimulant drugs in young people aged 16-24 years

Loi B, Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Schifano F

Giugno 2013

10th International Training Seminar in CHILD AND ADOLESCENT PSYCHIATRY. Planning the future: research and Evidence Based Practice (Bocca di Magra, SP, Italy)

Loi B, Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Schifano F

Aprile 2013

European Psychiatric Association Congress, Nice (France)

Behavioural changes in cocaine dependent patients after group-therapy

Di Paolo M, Chiappini S, Testa R, Pettorruso M, Di Cesare A, Sabetta L, Conte G

Aprile 2013

European Psychiatric Association Congress, Nice (France)

Validation of a diagnostic questionnaire based on DSM-IV criteria for Gambling

Sabetta L., Di Paolo M., Testa R., Chiappini S., Pettorruso M., Di Cesare A., Vilella C., Conte G.

Marzo 2012

European Psychiatric Association Congress, Prague (Czech Republic)

Evaluation of an Italian sample of gamblers with Dannon Ainhold gambling scale: a preliminary study.

Pascucci M, Pettorruso M, Righino E, Vilella C, Ciciarelli C, Di Cesare A, Chiappini S, Testa R, Conte G, Dannon PN

Marzo 2012

European Psychiatric Association Congress, Prague (Czech Republic)

Relationship between impulsivity, mood disorders and personality traits in a sample of pathological gamblers

Righino E, Pascucci M, Pettorruso M, Ciciarelli C, Di Cesare A, Chiappini S, Giallonardo V, Vilella C, Conte G.

Marzo 2012

European Psychiatric Association Congress, Prague (Czech Republic)

Psychosocial risk factors for postpartum depression: a descriptive sample of pregnant

Chiappini S, D'Oria L, Righino E, Bruschi A, Di Nardo F, Oliva G, Janiri L

Dicembre 2011

Global Addiction, Lisbon (Portugal)

Mobile phone use during adolescence: a new addiction?

Ciciarelli C, Vilella C, Righino E, Di Cesare A, Pettorruso M, Chiappini S, Pascucci M, Martinotti G, Di Nicola M, Janiri L, Conte G

Dicembre 2011

Global Addiction, Lisbon (Portugal)

Addiction: a therapeutic model for the restructuring of identity

Chiappini S, Pettorruso M, Pizzonia G, Conte G

Marzo 2011

European Psychiatric Association Congress, Vienna (Austria)

Psychopathologic aspects of obesity: psychodiagnostic evaluations of bariatric surgery applicants

Chiappini S, Ciciarelli C, Righino E, Pettorruso M, Di Cesare A, Conte GL

Maggio 2022

RADARS® System 16th Annual Scientific Virtual Meeting: Evolving Safety of Psychoactive Drugs

Does Over-the-Counter Mean Under the Radar? Focus On Over-The-Counter Drug Abuse

Oral presentations

Novembre 2021

VIII NPS conference-Washington (US)

FOCUS ON OVER-THE-COUNTER DRUG ABUSE: A SYSTEMATIC REVIEW ON THE DIVERSION OF ANTIHISTAMINES, COUGH MEDICINES, AND DECONGESTANTS

Dicembre 2019

International Pathways of Psychiatry - Percorsi emozionali e traiettorie di sviluppo nella Psichiatria del futuro - XII° Meeting - Roma (IT)

NPS and abuse of psychotropic drugs.

Aprile 2019

NPS conference- Maastricht (NL)

Prescription and over-the-counter drug misuse in the context of the NPS scenario; considering the pharmacovigilance approach to evaluate the abuse and misuse of medications.

Dicembre 2018

7th Young Psychiatric Network Meeting- Catania (IT)

The abuse of over-the-counter medications in the adolescents: the new phenomenon of 'pharming'.

Aprile 2018

Convegno Unosuquattro, Reggio Emilia (IT)

Epidemiologic, neuropharmacological and clinical evidences on cannabis and new psychoactive substances.

Marzo 2011

Leiden International Medical Student Conference, Leiden (Netherlands)

Psychopathologic aspects of obesity: psycho diagnostic evaluations of bariatric surgery applicants

Ai sensi del Decreto Legislativo n. 196 del 30.06.2003, autorizzo il destinatario del presente documento al trattamento dei miei dati personali. 196 del 30.06.2003, autorizzo il destinatario della presente ad utilizzare e trattare i miei dati personali contenuti nella presente.

29 Settembre 2023

Stefania Chiappini